Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhAST Trial: PhOx430 in Advanced Solid Tumours
NCT05495295Phase 1Active, not recruiting
- Sponsor
- Phost’in Therapeutics
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of phox430 in solid tumor, glioblastoma multiforme (GBM) and triple-negative breast cancer (TNBC), sponsored by Phost’in Therapeutics. Primary endpoints: Dose Limiting Toxicities at 6 weeks and Treatment-emergent Adverse Events up to 5 years. Started Jul 2022; status: active, not recruiting.
02
Drugs
phox430
03
Conditions
solid tumorglioblastoma multiforme (GBM)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05495295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05495295.